Valuation: Charles River Laboratories International, Inc.

Market Cap 13.37B 11.55B 10.85B 9.87B 18.55B 1,278B 18.86B 127B 49.71B 640B 50.19B 49.11B 2,127B P/E 2026 *
74.9x
P/E 2027 * 30x
Enterprise Value 15.48B 13.37B 12.56B 11.43B 21.48B 1,480B 21.84B 147B 57.56B 741B 58.13B 56.86B 2,464B EV / Sales 2026 *
3.96x
EV / Sales 2027 * 3.75x
Free-Float
95.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Charles River Laboratories International, Inc.

1 day-2.88%
1 week+5.49%
Current month+20.42%
1 month+21.18%
1 week 218.31
Extreme 218.313
232.17
1 month 176.12
Extreme 176.122
232.17
Current year 146.62
Extreme 146.619
232.17
1 year 146.62
Extreme 146.619
232.17
3 years 146.62
Extreme 146.619
232.17
5 years 146.62
Extreme 146.619
232.17
10 years 146.62
Extreme 146.619
232.17
Manager TitleAgeSince
Chief Executive Officer 56 2026-05-04
Director of Finance/CFO 58 2026-04-05
Chief Tech/Sci/R&D Officer 45 2026-01-11
Director TitleAgeSince
Chairman 75 1999-12-31
Director/Board Member 56 2026-05-04
Chairman 69 2026-05-04
Change 5-day change 1-year change 3-year change Capi.($)
-2.88%+5.49% - - 13.37B
-1.78%-1.68%+1.99%+13.84% 48.42B
+0.85%-0.70%+465.55%+579.03% 43.66B
-2.40%-0.23%+12.20%+70.22% 39.51B
-2.01%-0.85%+24.95%+7.51% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
-0.59%-2.06%+26.13%+117.79% 16.15B
+0.38%-3.23% - - 16.32B
+0.49%+0.92%+4.32%+22.16% 14.16B
-0.43%+4.70%+79.75%+29.11% 13.37B
Average -0.89%+0.49%+79.44%+111.17% 29.24B
Weighted average by Cap. -1.01%+0.59%+97.63%+134.68%

Financials

2026 *2027 *
Net sales 3.91B 3.38B 3.17B 2.89B 5.43B 374B 5.52B 37.19B 14.54B 187B 14.68B 14.37B 622B 4B 3.46B 3.25B 2.95B 5.55B 383B 5.64B 38.05B 14.88B 192B 15.02B 14.69B 637B
Net income 162M 140M 132M 120M 225M 15.54B 229M 1.55B 604M 7.78B 610M 597M 25.85B 428M 369M 347M 316M 594M 40.9B 603M 4.07B 1.59B 20.48B 1.61B 1.57B 68.07B
Net Debt 2.11B 1.82B 1.71B 1.56B 2.93B 202B 2.98B 20.09B 7.85B 101B 7.93B 7.76B 336B 1.63B 1.41B 1.32B 1.2B 2.26B 156B 2.3B 15.51B 6.06B 78.08B 6.12B 5.99B 259B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
26-08-14 CHF 225.03 -2.88%
26-08-13 CHF 231.70 -0.20%
26-08-12 CHF 232.17 +3.00%
26-08-11 CHF 225.42 +3.25%
26-08-10 CHF 218.31 +2.34%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
280.05USD
Average target price
281.00USD
Spread / Average Target
+0.34%

Quarterly revenue - Rate of surprise